Lifetime management for aortic stenosis: Planning for future therapies

J Cardiol. 2022 Jan 8:S0914-5087(21)00365-8. doi: 10.1016/j.jjcc.2021.12.010. Online ahead of print.ABSTRACTA shift to lifetime management has gained more focus with the approval of low-risk transcatheter aortic valve replacement (TAVR). This paper is therefore focused on the different approaches for lifetime management. Herein we discuss the procedural safety, durability, performance, and future options for each lifetime management strategy. In younger patients that elect to undergo surgical aortic valve replacement (SAVR), options for bioprosthetic failure are TAV-in-SAV or redo SAVR. Among patients that undergo TAVR, options for valve failure include TAVR explant with SAVR or TAV-in-TAV. Additionally, there are patients who may require a third valvular intervention. The initial therapy may limit re-intervention options down the road. This review discusses how options for future therapies affect the decision of SAVR vs TAVR in younger patients.PMID:35016808 | DOI:10.1016/j.jjcc.2021.12.010

Source: Journal of Cardiology - January 12, 2022 Category: Cardiology Authors: Craig Basman Luigi Pirelli Varinder P Singh Carl D Reimers Jonathan Hemli Derek R Brinster Nirav C Patel S Jacob Scheinerman Chad A Kliger Source Type: research